PHVS

PHVS

USD

Pharvaris N.V. Ordinary Shares

$21.640-0.842 (-3.746%)

Reaalajas hind

Healthcare
Biotehnoloogia
Šveits

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$22.482

Kõrge

$22.482

Madal

$21.585

Maht

0.14M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

1.4B

Tööstusharu

Biotehnoloogia

Riik

Switzerland

Kauplemisstatistika

Keskmine maht

0.19M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $11.51Praegune $21.640Kõrge $26.33

Seotud uudised

GlobeNewswire

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living

Vaata rohkem
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
Analyst Upgrades

HC Wainwright & Co. Initiates Coverage On Pharvaris with Buy Rating, Announces Price Target of $60

HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on Pharvaris with a Buy rating and announces Price Target of $60.

Vaata rohkem
HC Wainwright & Co. Initiates Coverage On Pharvaris with Buy Rating, Announces Price Target of $60
Analyst Upgrades

B of A Securities Upgrades Pharvaris to Neutral, Raises Price Target to $27

B of A Securities analyst Tazeen Ahmad upgrades Pharvaris from Underperform to Neutral and raises the price target from $16 to $27.

Vaata rohkem
B of A Securities Upgrades Pharvaris to Neutral, Raises Price Target to $27

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.